Lakefront Biotherapeutics NV
GLPGF
$28.08
$0.000.00%
OTC PK
| 03/31/2026 | 12/31/2025 | 06/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 110.30% | 3,492.13% | -1,341.01% | -1,341.01% | -264.83% |
| Total Depreciation and Amortization | -- | -- | 112.11% | 112.11% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -283.40% | 80.11% | 219.08% | 219.08% | 171.77% |
| Change in Net Operating Assets | -83.45% | -1,482.91% | 18.51% | 18.51% | 139.52% |
| Cash from Operations | -133.74% | -1.23% | -72.66% | -72.66% | 69.43% |
| Capital Expenditure | 97.37% | 65.42% | -31.96% | -31.96% | -31.99% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -92.00% | 12.11% | -504.66% | -504.66% | 2,411.23% |
| Other Investing Activities | 9.14% | 17.59% | 45.56% | 45.56% | 61.58% |
| Cash from Investing | -20.87% | 24.72% | 19.33% | 19.33% | 176.93% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 49.55% | 74.75% | 43.61% | 43.61% | 13.44% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 44.99% | 70.51% | 40.53% | 40.53% | 16.10% |
| Foreign Exchange rate Adjustments | 158.76% | -211.87% | -513.13% | -513.13% | -352.35% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -152.41% | 109.48% | -3,576.17% | -3,576.17% | 145.47% |